List of Excipients in API dapagliflozin and metformin hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing dapagliflozin and metformin hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | XIGDUO | dapagliflozin and metformin hydrochloride | 0310-6270 | ANHYDROUS LACTOSE | 2031-05-12 |
| AstraZeneca Pharmaceuticals LP | XIGDUO | dapagliflozin and metformin hydrochloride | 0310-6270 | CARBOXYMETHYLCELLULOSE SODIUM | 2031-05-12 |
| AstraZeneca Pharmaceuticals LP | XIGDUO | dapagliflozin and metformin hydrochloride | 0310-6270 | CELLULOSE, MICROCRYSTALLINE | 2031-05-12 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for dapagliflozin and metformin hydrochloride
Excipient focus: ANHYDROUS LACTOSE
dapagliflozin and metformin hydrochloride drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and metformin hydrochloride | 0310-6270 |
| PRASCO LLC | dapagliflozin and metformin hydrochloride | 66993-362 |
| >Company | >Ingredient | >NDC |
dapagliflozin and metformin hydrochloride drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOXYMETHYLCELLULOSE SODIUM
dapagliflozin and metformin hydrochloride drug variants containing CARBOXYMETHYLCELLULOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and metformin hydrochloride | 0310-6270 |
| PRASCO LLC | dapagliflozin and metformin hydrochloride | 66993-362 |
| >Company | >Ingredient | >NDC |
dapagliflozin and metformin hydrochloride drug variants not containing CARBOXYMETHYLCELLULOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
dapagliflozin and metformin hydrochloride drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and metformin hydrochloride | 0310-6270 |
| PRASCO LLC | dapagliflozin and metformin hydrochloride | 66993-362 |
| >Company | >Ingredient | >NDC |
dapagliflozin and metformin hydrochloride drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
dapagliflozin and metformin hydrochloride drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and metformin hydrochloride | 0310-6270 |
| PRASCO LLC | dapagliflozin and metformin hydrochloride | 66993-362 |
| >Company | >Ingredient | >NDC |
dapagliflozin and metformin hydrochloride drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2208
dapagliflozin and metformin hydrochloride drug variants containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and metformin hydrochloride | 0310-6270 |
| PRASCO LLC | dapagliflozin and metformin hydrochloride | 66993-362 |
| >Company | >Ingredient | >NDC |
dapagliflozin and metformin hydrochloride drug variants not containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
dapagliflozin and metformin hydrochloride drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and metformin hydrochloride | 0310-6270 |
| PRASCO LLC | dapagliflozin and metformin hydrochloride | 66993-362 |
| >Company | >Ingredient | >NDC |
dapagliflozin and metformin hydrochloride drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
dapagliflozin and metformin hydrochloride drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and metformin hydrochloride | 0310-6270 |
| PRASCO LLC | dapagliflozin and metformin hydrochloride | 66993-362 |
| >Company | >Ingredient | >NDC |
dapagliflozin and metformin hydrochloride drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch